AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.11
+0.33%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +9.0%
- EBITDA
- -59.8%
- EPS
- —
Three-year CAGR
- Revenue
- +336.9%
- EBITDA
- -44.8%
- EBIT
- -43.5%
- Net income
- -44.9%
- EPS
- +5.6%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026